Damage of serotonergic axons and immunolocalization of Hsp27, Hsp72, and Hsp90 molecular chaperones after a single dose of MDMA administration in Dark Agouti rat: Temporal, spatial, and cellular patterns
Csaba Ádori, Rómeó D. Andó, Gábor G. Kovács, György Bagdy
The Journal of Comparative Neurology January 1, 2006 DOI: 10.1002/cne.20994 via OpenAlex
Summary
AI-generated from the abstractMDMA (ecstasy) causes lasting damage to the brain's serotonin system. In Dark Agouti rats, a single injection of MDMA at doses of 7.5, 15, or 30 mg/kg reduced the density of serotonin-producing axons throughout the brain 3 and 7 days later. Three days after treatment, a dose-dependent increase in the stress protein Hsp27 appeared in star-shaped glial cells (astrocytes) in several cortical areas and the hippocampus CA1 region, but not in other brain regions like the caudate putamen. The hippocampus CA1 showed both increased Hsp27 and another marker of glial activation (GFAP), suggesting particular vulnerability. High-dose MDMA also triggered Hsp72 in neurons, indicating effects beyond serotonin cells.
Study at a glance
| Characteristics | Animal experiment Peer reviewed |
|---|---|
| Population | Dark Agouti rat brains |
| Intervention | MDMA |
| Dose | 7.5, 15, and 30 mg/kg single intraperitoneal (i.p.) doses |
| Duration | 3 and 7 days after treatment |
| Topics | MDMA Serotonin |
| Keywords | Biology Immunostaining Hippocampus |
| Citations | 51 |
| Key finding | MDMA caused a dose-dependent increase in Hsp27-immunoreactive protoplasmic astrocytes in cortical areas and hippocampus CA1, with co-occurrence of Hsp27 and GFAP response only in hippocampus CA1, suggesting regional differences in astroglial response and particular vulnerability of the hippocampus CA1. |
Abstract
3,4-Methylenedioxymethamphetamine (MDMA, "ecstasy") causes long-term disturbance of the serotonergic system. We examined the temporal, spatial, and cellular distribution of three molecular chaperones, Hsp27, Hsp72, and Hsp90, 3 and 7 days after treatment with 7.5, 15, and 30 mg/kg single intraperitoneal (i.p.) doses of MDMA in Dark Agouti rat brains. Furthermore, we compared the immunostaining patterns of molecular chaperones with serotonergic axonal-vulnerability evaluated by tryptophan-hydroxylase (TryOH) immunoreactivity and with astroglial-activation detected by GFAP-immunostaining. There was a marked reduction in TryOH-immunoreactive axon density after MDMA treatment in all examined areas at both time points. Three days after treatment, a significant dose-dependent increase in Hsp27-immunoreactive protoplasmic astrocytes was found in the cingulate, frontal, occipital, and pyriform cortex, and in the hippocampus CA1. However, there was no increase in astroglial Hsp27-immunoreactivity in the caudate putamen, lateral septal nucleus, or anterior hypothalamus. A significant increase in the GFAP immunostaining density of protoplasmic astrocytes was found only in the hippocampus CA1. In addition, numerous strong Hsp72-immunopositive neurons were found in some brain areas only 3 days after treatment with 30 mg/kg MDMA. Increased Hsp27-immunoreactivity exclusively in the examined cortical areas reveals that Hsp27 is a sensitive marker of astroglial response to the effects of MDMA in these regions of Dark Agouti rat brain and suggests differential responses in astroglial Hsp27-expression between distinct brain areas. The co-occurrence of Hsp27 and GFAP response exclusively in the hippocampus CA1 may suggest the particular vulnerability of this region. The presence of strong Hsp72-immunopositive neurons in certain brain areas may reflect additional effects of MDMA on nonserotonergic neurons.